At a glance
- Originator Merck & Co
- Class
- Mechanism of Action Growth hormone releasing factor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Somatotropin deficiency
Most Recent Events
- 06 Jun 2001 No-Development-Reported for Somatotropin deficiency in USA (Unknown route)
- 15 Apr 1998 Preclinical development for Somatotropin deficiency in USA (Unknown route)